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Recent studies indicate that long interspersed
nuclear element-1 (L1) are mobilized in the genome
of human neural progenitor cells and enhanced in
Rett syndrome and ataxia telangiectasia. However,
whether aberrant L1 retrotransposition occurs in
mental disorders is unknown. Here, we report high
L1 copy number in schizophrenia. Increased L1
was demonstrated in neurons from prefrontal cortex
of patients and in induced pluripotent stem (iPS)
cell-derived neurons containing 22q11 deletions.
Whole-genome sequencing revealed brain-specific
L1 insertion in patients localized preferentially to
synapse- and schizophrenia-related genes. To study
the mechanism of L1 transposition, we examined
perinatal environmental risk factors for schizo-
phrenia in animal models and observed an increased
L1 copy number after immune activation by poly-I:C
or epidermal growth factor. These findings suggest
that hyperactive retrotransposition of L1 in neurons
triggered by environmental and/or genetic risk fac-
tors may contribute to the susceptibility and patho-
physiology of schizophrenia.
INTRODUCTION
Mental disorders including schizophrenia, bipolar disorder, and
major depression affect a large proportion of the global popula-
tion and have a major negative economic impact. Twin, family,
and adoption studies indicate the complex involvement of both
genetic and environmental factors for these diseases (Keshavan
et al., 2011). Despite their apparent heritability, however, causa-306 Neuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc.tive genetic factors are mostly unknown except for rare cases
of schizophrenia associated with chromosomal abnormalities
(Brandon and Sawa, 2011; Cook andScherer, 2008; Karayiorgou
et al., 2010). On the other hand, environmental risk factors
including prenatal infection (Brown, 2006) and obstetric compli-
cations, such as neonatal hypoxia, embryonic ischemia, and
gestational toxicosis (Lewis and Murray, 1987), are well-estab-
lished risk factors for schizophrenia. However, it is not clarified
how these environmental risk factors interact with genomic
factors.
Accumulating evidence indicates that genomic DNA in the
brain contains distinctive somatic genetic variations compared
with nonbrain tissues (Poduri et al., 2013). These genetic signa-
tures include brain-specific somatic mutations (Poduri et al.,
2013), chromosomal aneuploidy (Rehen et al., 2005; Yurov
et al., 2007), chromosomal microdeletion (Shibata et al., 2012),
and the genome dynamics of nonlong terminal repeat (LTR) ret-
rotransposons (Baillie et al., 2011; Evrony et al., 2012;Muotri and
Gage, 2006). These observed somatic variations are hypothe-
sized to contribute to the generation of functionally diversified
brain cells (Muotri and Gage, 2006).
Among the known retrotransposons, only long interspersed
nucleotide element-1 (L1) has autonomous retrotransposition
activity. Full-length L1 elements include a 50 UTR, two open
reading frames (ORFs), and a 30 UTR (Figure 1A). Encoded prod-
ucts from the ORFs contain activities required for retrotransposi-
tion and are employed in the insertion of new L1 copies as well as
nonautonomous retrotransposons such as Alu and SVA (Cor-
daux and Batzer, 2009). Recent studies indicate that engineered
L1 has retrotransposition activity in neural progenitor cells from
rat hippocampus (Muotri et al., 2005), human fetal brain (Coufal
et al., 2009), and human embryonic stem cells (Coufal et al.,
2009). These in vitro findings were confirmed in human L1 trans-
genic mice in vivo (Muotri et al., 2005). Adult human brain cells
also showed increased L1 copy number compared with non-
brain tissues (Coufal et al., 2009). Moreover, retrotransposition
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Figure 1. Increase of Brain L1 Copy Number
in Schizophrenia
(A) Structure of L1 andmap of the primers. Primers
and probes are fromprevious studies (Coufal et al.,
2009; Muotri et al., 2010) or designed for this study
(Table S4). (B) Summary of the demographic vari-
ables of brain samples. (C) L1 copy number in set I.
(D) Neuronal nuclei isolation. Left: example of
NeuN-based nuclei sorting of brain cells from a
patient with schizophrenia. Right: microscopic
confirmation of isolated nuclei. The purity of each
fraction was >95% and 99.9% for NeuN+ and
NeuN, respectively. (E) Neuronal L1 copy num-
ber in set II. In quantitative real-time PCR, L1 copy
number was measured with HERVH or SATA as
internal controls. The ratio of prefrontal cortex to
liver (for set I) or neurons to nonneurons (for set II)
was calculated and then normalized relative to the
average value of control samples. Values were
represented as open or closed diamonds as well
as box plots. The DCt values of L1 and control
probes were not significantly different between
diagnostic groups in set I or set II. p values were
determined by the Mann-Whitney U test. PMI,
postmortem interval; CT, controls; SZ, schizo-
phrenia; MD, major depression; BD, bipolar dis-
order; PI, propidium iodide. See also Tables S1
and S4 and Figures S1 and S2.
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Increased L1 Copy Number in Schizophreniais active in MeCP2 mouse models and patients with Rett syn-
drome, indicating a role for this mechanism in thisMendelian dis-
order (Muotri et al., 2010). Together, these findings suggest theNeuron 81, 306–313hypothesis that L1 retrotransposition
may also be involved in the pathophysi-
ology of mental disorders.
In this study, we quantified L1 copy
number in genomic DNA derived from
postmortem brains of patients with major
mental disorders.We report significant in-
creases of L1 content in the prefrontal
cortex of patients with schizophrenia. To
confirm this finding, we quantified L1
copy number in neurons and nonneurons
from a second, independent patient
cohort using NeuN-based cell sorting
(Iwamoto et al., 2011; Rehen et al.,
2005; Spalding et al., 2005) and found
that L1 copy number in neurons was
increased in patients with schizophrenia.
We next quantified L1 copy number in
the animal models that are known to
disturb early neural development. These
included maternal polyriboinosinic-poly-
ribocytidilic acid (poly-I:C) injection in
mice (Meyer and Feldon, 2012; Giovanoli
et al., 2013) and chronic epidermal
growth factor (EGF) injection to infant ma-
caques (Nawa et al., 2000). We found that
genomic DNA of brains from both animalmodels showed increased L1 copy number, addressing the
importance of environmental factors during perinatal and post-
natal stages. We also found that the increased L1 copy number, January 22, 2014 ª2014 Elsevier Inc. 307
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Figure 2. Increase of Brain L1 Copy Number
in Animal Models
(A) Brain L1 content in thematernal poly-I:Cmodel.
p values were determined by the Mann-Whitney U
test. Values were represented as open or closed
diamonds aswell as box plots. (B) Brain L1 content
in chronic EGF or haloperidol-treated macaque
models. Error bars indicate SDs. The comparative
Ct method, with 5S-rRNA as an internal control,
was used. The ratio of prefrontal cortex to liver (for
poly-I:C model) or prefrontal gray matter to NeuN-
sorted nonneurons in white matter (for macaque
models) was calculated and then normalized
relative to the average value of control samples.
See also Table S4.
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Increased L1 Copy Number in Schizophreniain the neurons derived from induced pluripotent stem (iPS) cells
of schizophrenia patients with 22q11 deletion. The 22q11 dele-
tion is a well-defined genetic factor and is one of the highest
risk factors for schizophrenia, affecting about 1%–2% of schizo-
phrenia patients (Karayiorgou et al., 2010). Finally, we performed
whole-genome sequencing (WGS) analysis of brain and liver in
controls and patients. Comparison of brain-specific L1 insertion
sites revealed that brain-specific L1 insertion in patients is
enriched in or near genes related to synaptic function and neuro-
psychiatric diseases. These results suggest that increased retro-
transposition of L1 in neurons, which was triggered by genetic
component and/or environmental factors at the early neural
development, could contribute to the susceptibility and patho-
physiology of schizophrenia.
RESULTS
Increased Brain L1 Content in Schizophrenia
We used postmortem prefrontal cortex samples of patients with
schizophrenia, bipolar disorder, and major depression as well as
control subjects for analysis in set I. The demographic variables
are summarized in Figure 1B. We quantified L1 copy number of
postmortem prefrontal cortex and liver in each subject by quan-
titative RT-PCR with two different internal controls, which were
designed for human endogenous retrovirus (HERVH) and
alpha-satellite (SATA). We found a significant increase in the
brain L1ORF2 content in patients with schizophrenia (Figure 1C).
A tendency toward copy number increase was also observed in
mood disorders and in other L1 probes in schizophrenia (Fig-
ure S1 available online).
Somatic L1 retrotransposition was primarily found in neuronal
cells (Kuwabara et al., 2009). To confirm the increased brain L1
copy number in schizophrenia and address whether this copy
number increase is due to alteration of the neuronal genome,
we examined an independent prefrontal cortex sample set (set
II). We separated neuronal and nonneuronal nuclei from frozen
brains using NeuN-based cell sorting (Figure 1D) (Iwamoto
et al., 2011). NeuN is expressed in vertebrate neurons, and its
antibody can be used for labeling neuronal nuclei (Mullen et al.,
1992). We quantified L1ORF2 copy number of genomic DNA
derived from neurons (NeuN-positive nuclei) and nonneurons
(NeuN-negative nuclei) and then calculated the neuron-to-non-308 Neuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc.neuron ratio. We found a significant increase of neuronal
L1ORF2 content in schizophrenia in two different internal con-
trols (Figure 1E). The copy number of the other L1 probes tested
also showed significant increase in schizophrenia compared to
controls in SATA-normalized data, and similar tendency toward
copy number increase was observed in HERVH-normalized
data (Figure S1 and data not shown).
Assessment of Confounding Factors
We assessed the effect of confounding factors on L1 content
(Table S1). Among the demographic variables tested, sample
pH showed a weak correlation with L1ORF2 content in set II
but not in set I. Several variables also showed weak correlations,
but none showed consistency across the different internal con-
trol probes or across the two different sample sets.
To consider the possible effect of antipsychotics, we exam-
ined L1 copy number in a human neuroblastoma cell line cultured
with haloperidol or risperidone for 8 days. Both antipsychotics
did not modify the L1 copy number at their low or high concen-
trations (Figure S2). Together with the fact that the lifetime intake
of antipsychotics, which was estimated as fluphenazine milli-
gram equivalents, did not correlate with L1 copy number in
both brain sets (Table S1), medication status did not affect our
results.
L1 Quantification in Animal Models
To assess the potential roles of environmental factors on
increased L1 copy number, we employed two different animal
models that mimic environmental risk factors that affect early
neural development. They included maternal poly-I:C injection
in mice and chronic EGF injection to neonatal macaques. The
poly-I:C, which mimics viral double-stranded RNA, injection to
pregnant mice induces elevated maternal immune activation,
and the offspring is known to show schizophrenia-like behavioral
alterations such as impairments of prepulse inhibition and social
behavior at the later stage (Meyer and Feldon, 2012). Pregnant
mice received a single intraperitoneal injection of poly-I:C. L1
copy number in the prefrontal cortex of offspring was tested at
postnatal day 21. We found that significant elevation of L1 copy
number at all the tested probes compared to controls (Figure 2A).
We then examined the L1 copy number in macaques treated
with EGF during neonatal period. Perinatal and postnatal
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Figure 3. L1 Content in Neurons Derived from iPS Cells of Schizophrenia Patients with 22q11 Deletions
The comparative Ct method, with SATA as an internal control, was used. The ratio of NeuN-sorted neurons to nonneurons was calculated and then normalized
relative to average value of control samples. Error bars indicate SDs. See also Table S4 and Figure S3.
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Increased L1 Copy Number in Schizophreniaperturbation of EGF is known to evoke schizophrenia-like phe-
notypes, including deficits in prepulse inhibition, latent inhibition,
social interaction, and working memory, in adulthood (Nawa
et al., 2009, 2000).The neonatal macaques (n = 2) subcutane-
ously received EGF for seven times over 11 days. After 4 and 7
years from treatment, L1 copy number in the prefrontal cortex
was tested. In addition, chronic haloperidol-treated macaques
(n = 3) were also tested. Due to unavailability of other tissues,
we isolated nonneuronal nuclei from frozen white matter and
calculated the grey matter-to-nonneuron ratio in each subject.
Although statistical approach could not be applied, we observed
increase of L1 copy number in EGF-treatedmacaques, but not in
the haloperidol-treated macaques, compared to controls (Fig-
ure 2B). Taken together, these results suggest that early environ-
mental factors play important roles in the L1 content in the brain.
We further confirmed that chronic haloperidol treatment did not
influence L1 copy number in this model.
L1 Quantification in the iPS Cells of Schizophrenia
Patients with 22q11 Deletion
We next assessed the importance of genetic risk factor on the L1
copy number in brain. We quantified L1 copy number in the neu-
rons derived from iPS cells of schizophrenia patients with 22q11
deletion (n = 2) as well as controls (n = 2) (Figure S3). The iPS cells
were established from the fibroblasts according to the previouslydeveloped method (Imaizumi et al., 2012; Takahashi et al., 2007;
M.T., unpublished data). To estimate the L1 copy number, we
used two independently established iPS cell lines per patient.
After induction of neuronal cells (Imaizumi et al., 2012), we iso-
lated neuronal nuclei by NeuN-based sorting (Figure S3). We
then examined L1 copy number and calculated the neuron-to-
nonneuron ratio. Compared to controls, we observed consistent
increase of L1 copy number in iPS cell-derived neurons of
patients with schizophrenia with 22q11 deletion (Figure 3). These
results suggest that the well-defined strong genetic risk factor
also plays an important role in the L1 content in the brain.
Identification and Comparison of Brain-Specific L1
Transposition
We next performed WGS of brain and liver DNA from same sub-
jects by self-assembling DNA nanoarray technology (Drmanac
et al., 2010). For this experiment, schizophrenia patients (n = 3)
and control subjects (n = 3) were selected to match age, PMI,
gender, brain pH, and race from set I. Selected patients ex-
hibited increased L1 content by quantitative RT-PCR assay,
compared to average L1 content of the controls and selected
control subjects. The WGS metrics and identified variations
were summarized in Table S2. Distribution of the detected mo-
bile elements was almost equal between the tissues and across
subjects, and over the half of the identified elements was relatedNeuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc. 309
Control
Term Count p value FE
height 4 0.0132 7.7
scoliosis 3 0.0316 10.3
Schizophrenia
Term Count p value FE
schizophrenia;
bipolar disorder
schizoaffective disorder; 5 0.0125 5.2
schizophrenia 29 0.0135 1.6
hypertension 20 0.0194 1.7
bipolar disorder 13 0.0373 1.9
A
Control
Term Count p value
GO:0005856~cytoskeleton 74 5.92E-04
GO:0005509~calcium ion binding 56 0.0031
GO:0005930~axoneme 9 0.0095
GO:0035085~cilium axoneme 7 0.0289
GO:0003779~actin binding 26 0.0322
GO:0044425~membrane part 240 0.0387
GO:0016010~dystrophin-associated glycoprotein complex 6 0.0405
Schizophrenia
Term Count p value
GO:0045202~synapse 57 3.09E-09
GO:0030054~cell junction 64 8.57E-06
GO:0044459~plasma membrane part 187 1.49E-05
GO:0004674~protein serine/threonine kinase activity 58 2.27E-05
GO:0044456~synapse part 38 4.44E-05
GO:0004672~protein kinase activity 72 7.45E-05
GO:0030554~adenyl nucleotide binding 147 1.09E-04
GO:0005856~cytoskeleton 126 1.19E-04
GO:0005488~binding 820 1.25E-04
GO:0006468~protein amino acid phosphorylation 76 1.75E-04
GO:0006796~phosphate metabolic process 100 1.98E-04
GO:0006793~phosphorus metabolic process 100 1.98E-04
GO:0016773~phosphotransferase activity, alcohol group as acceptor 80 2.31E-04
GO:0001882~nucleoside binding 148 2.52E-04
GO:0005524~ATP binding 138 2.63E-04
GO:0001883~purine nucleoside binding 147 2.77E-04
GO:0032559~adenyl ribonucleotide binding 139 3.43E-04
GO:0017076~purine nucleotide binding 169 4.19E-04
GO:0000166~nucleotide binding 190 0.0011
GO:0014069~postsynaptic density 17 0.0011
GO:0032553~ribonucleotide binding 161 0.0012
GO:0032555~purine ribonucleotide binding 161 0.0012
GO:0043167~ion binding 323 0.0015
GO:0016043~cellular component organization 204 0.0018
GO:0043169~cation binding 318 0.0021
GO:0016310~phosphorylation 83 0.0021
GO:0046872~metal ion binding 315 0.0025
GO:0016301~kinase activity 85 0.0032
GO:0005737~cytoplasm 489 0.0037
GO:0008092~cytoskeletal protein binding 58 0.0045
GO:0007155~cell adhesion 74 0.0049
GO:0022610~biological adhesion 74 0.0052
GO:0019898~extrinsic to membrane 54 0.0053
GO:0043687~post-translational protein modification 108 0.0169
GO:0030030~cell projection organization 45 0.0219
GO:0005509~calcium ion binding 88 0.0234
GO:0015629~actin cytoskeleton 33 0.0439
B
insertion site CT1 CT2 CT3 average ratio
intergenic (low) 0.64 0.76 0.69 0.69
intragenic (low) 0.36 0.24 0.31 0.31
intron (low) 0.90 1.00 0.99 0.96
exon (low) 0.10 0.00 0.01 0.04
intergenic (high) 0.65 0.81 0.69 0.72
intragenic (high) 0.35 0.19 0.31 0.28
intron (high) 0.88 1.00 0.99 0.96
exon (high) 0.12 0.00 0.01 0.04
C
90 0.0473
GO:0045211~postsynaptic membrane 21 0.0487
insertion site SZ1 SZ2 SZ3 average ratio
intergenic (low) 0.72 0.63 0.58 0.64
intragenic (low) 0.28 0.37 0.42 0.36
intron (low) 0.99 0.98 0.98 0.98
exon (low) 0.01 0.02 0.02 0.02
intergenic (high) 0.74 0.63 0.57 0.65
intragenic (high) 0.26 0.37 0.43 0.35
intron (high) 0.99 0.98 0.98 0.98
exon (high) 0.01 0.02 0.02 0.02
Control
Schizophrenia
GO:0016772~transferase activity, transferring phosphorus-containing groups
Figure 4. Insertion Site, Gene Ontology, and Disease Association Analyses
(A) L1-insertion site analysis. Proportion of intergenic and intragenic L1 insertion and that of intronic and exonic L1 insertion are given. The low and high mean
estimated proportions based on both less and stringent criteria are given. Note that ratios are not significantly different between patients and controls. (B) Gene
ontology analysis. p values indicate Bonferroni-corrected modified Fisher’s exact test p value. The terms showing p < 0.05 are shown for both groups. (C)
Disease-association analysis. p values indicate noncorrected modified Fisher’s exact test p value. FE, fold enrichment. In both analyses, gene lists generated by
the stringent criteria were used. See also Tables S2 and S3 and Figure S4.
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Increased L1 Copy Number in Schizophreniato the L1-Hs (Figure S4). Among the detected mobile element
insertion sites in each sequenced sample, we first identified
brain-specific L1 insertions in each subject (Tables S2 and S3).
Although the total number of brain-specific L1 insertion tended
to be higher in schizophrenia patients, this was not statistically
significant, most likely due to the limited sample size and high
interindividual variation. We then compared genomic locations
of the insertion sites of brain-specific L1 between patients and
controls (Figure 4A). The inter-to-intragenic L1 insertion ratio as
well as exonic-to-intronic L1 insertion ratio did not differ between
patients and controls. We then compared the affected genes by
brain-specific L1 insertion by gene ontology approach. This310 Neuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc.analysis revealed that the number of enriched terms is higher
in schizophrenia than controls, in spite that the number of
brain-specific L1 insertions did not significantly differ. We found
that neuronal function-related terms such as synapse and
protein phosphorylation are clearly overrepresented in schizo-
phrenia compared to controls (Figure 4B). In addition, disease-
association analysis revealed that affected genes in patients
are specifically enriched in terms related to schizophrenia and bi-
polar disorder, while those in controls are enriched in nonneur-
opsychiatric terms such as height and scoliosis (Figure 4C).
These results were consistently confirmed when we used less
stringent definition of brain-specific L1 insertion (Figure S4). In
Neuron
Increased L1 Copy Number in Schizophreniaaddition, enrichment of the L1-inserted genes to the terms
related to neuropsychiatric disorders in schizophrenia was also
detected by the ingenuity pathway analysis (IPA) (Figure S4).
DISCUSSION
We report that the neuronal genome of schizophrenia contains
higher copy number of a retrotransposon, L1. To validate this
finding, we utilized iPS cells from patients with schizophrenia
carrying the 22q11 deletion and observed an increase in L1
copy number in iPS cell-derived neurons. Moreover, using
WGS, we found that L1 preferentially inserted into genes related
to synaptic functions and schizophrenia. Animal model studies
showed that environmental factors related to infection or inflam-
mation that disturbs early neurodevelopmental processes
increase L1 copy number in the brain. Collectively, these results
suggest that hyperactive L1 retrotransposition into critical
genes during neural development, triggered by genetic and/or
environmental factors, contribute to the pathophysiology of
schizophrenia. Our results significantly expand the range of
neuropsychiatric illnesses linked to aberrant L1 retrotransposi-
tion, from Mendelian disease patients with MECP2 mutations
in Rett syndrome (Muotri et al., 2010) and ATM mutations in
ataxia telangiectasia (Coufal et al., 2011) to schizophrenia, a
complex mental disorder.
The observed increase of L1 content in schizophrenia was not
due to, or modulated by, biological or experimental artifacts,
because changes were measured in two independent patient
cohorts and each result was confirmed with two different internal
controls. Although the L1 region showing significant increases
differed between the two brain sets, this is attributable to cohort
differences amplified by the strict threshold we employed. Actu-
ally, a significant increase of L1 content was widely observed in
all probes in the SATA-normalized data in set II, where neuronal
L1 copy number was directly examined (Figure S1). In addition,
from the data analysis utilizing lifetime intake of antipsychotics
of patients, and from the cell culture and macaque experiments,
we conclude that antipsychotics do not affect L1 copy number in
the brain. A significant increase was also observed in patients
with mood disorders in one internal control in set I (Figure 1C).
Future work will clarify whether there are L1 content increases
in other mental disorders using larger and/or stratified patient
cohorts.
L1 retrotransposition has been detected during adult neuro-
genesis in the rat hippocampus, indicating that neural progenitor
cells retain retrotransposition activity even in adult stages (Muotri
et al., 2009). However, we analyzed potential confounding fac-
tors, including age, age of onset, and duration of illness, and
did not observe any significant correlation with L1 copy number
in the brain. The transcript level of L1 in adult brain sample was
also increased in patients compared to controls (data not
shown). However, elevated expression is unlikely to contribute
to increase of L1 copy number in patients, as significant increase
of L1 transcripts was detected only in the 50 region of L1 such as
50 UTR and ORF1. These results suggest that L1 copy number
does not globally increase with aging and that the variation of
L1 copy number in patients is probably confined to early neuro-
developmental stages, at least in the prefrontal cortex. Thisprediction would be consistent with the neurodevelopmental hy-
pothesis of schizophrenia, where abnormalities during critical
early periods of brain development may trigger the later appear-
ance of clinical symptoms (Bloom, 1993; Murray et al., 1992;
Weinberger, 1987).
In Rett syndrome, increased L1 copy number in human brain
was linked to mutations in MECP2 (Muotri et al., 2010) and
MeCP2 knockout mice also showed increased L1 content
(Muotri et al., 2010). It has also been suggested that SOX2 and
MECP2 regulate L1 transcription in neurons (Muotri et al.,
2005; Yu et al., 2001). However, we did not observe a significant
correlation between MECP2 or SOX2 expression and brain L1
content, by using the previously performed gene expression
analyses on the same sample sets (Iwamoto et al., 2004, 2005)
(data not shown). In addition, patients with high levels of L1
copy number (two schizophrenia and one major depression in
set I, and two schizophrenia patients in set II) did not show
altered MECP2 or SOX2 expression levels (data not shown).
These findings suggest that the molecular mechanism of
increased L1 in schizophrenia is different from Rett syndrome.
In this study, we found that both early environmental and well-
defined strong genetic factors for schizophrenia are involved in
the increase of L1 copy number in the brain. A recent study using
the poly-I:C model indicated that the offspring of this model
had exacerbated schizophrenia-like phenotypes, if they were
exposed to environmental stress during puberty, suggesting
that early environmental factors can lower the threshold for onset
of schizophrenia (Giovanoli et al., 2013). Therefore, increased L1
insertions induced by environmental factors may increase the
susceptibility to schizophrenia by disrupting synaptic and
schizophrenia-related genes in neurons, rather than being a
direct cause of the disease. On the other hand, the pathological
consequences of increased L1 content in neurons derived from
iPS cells of schizophrenia patients with 22q11 deletions remain
unclear. We chose patients with 22q11 deletions to examine
L1 dynamics where there is a well-defined strong genetic risk
for schizophrenia. InMeCP2-knockoutmice, Rett-like behavioral
abnormalities could be rescued by the re-expression of wild-
type MeCP2 at both young and adult stages (Cobb et al.,
2010; Ehninger et al., 2008), suggesting that L1 content itself
may not be directly causal to disease phenotypes but instead
modulate phenotypic variability among patients (Muotri et al.,
2010). Similarly, we speculate that the L1 increase in schizo-
phrenia patients with 22q11 deletions is likely to modulate phe-
notypes of schizophrenia rather than a direct cause, because
many genes related to schizophrenia, such as TBX-1, SEPT5,
COMT, and PRODH, are located within the deletion (Hiroi
et al., 2013; Karayiorgou et al., 2010). Nevertheless, our findings
will facilitate further studies of the mechanism of increased L1
retrotransposition associated with schizophrenia.
Our WGS analysis could not detect increased brain-specific
L1 insertions in schizophrenia; however, we found that L1 inser-
tions were more frequent in genes for synaptic function and
schizophrenia relative to controls. Evrony et al. cloned one L1
insertion event from 300 single neurons and showed that 2 of
83 cortical neurons from an individual had this insertion, but
detection of such a low level mosaic insertion in bulk brain tissue
of the same individual was difficult and needed optimizationNeuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc. 311
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missed in our WGS analysis. Apart from L1, nonautonomous ret-
rotransposons such as Alu and SVA also show an increased
copy number in the brain, possibly via the aid of L1ORF products
(Baillie et al., 2011) and their copy number might also be
increased in patients. Further studies on the neuronal genome
of patients with mental disorders, and supporting mechanistic
evidence from animal and cellular models, may establish a
broader role for instability of neural genome in the pathophysi-
ology of schizophrenia. We expect that our findings will promote
the further study of genomic instability in disease etiology due to
L1 retrotransposition in brain development.
EXPERIMENTAL PROCEDURES
Postmortem Samples
Postmortem brain and liver samples were obtained from the Stanley Medical
Research Institute. The demographics are summarized in Figure 1B and are
described at the web site (http://www.stanleyresearch.org/). Ethics commit-
tees of RIKEN and the University of Tokyo Faculty of Medicine approved the
study.
Animal Models
Animal experiments were performed in accordancewith the NIHGuidelines for
the Care and Use of Laboratory Animals and guidelines of relevant facilities.
For poly I:C model, pregnant mice (C57BL/6) received either a single intraper-
itoneal injection of poly-I:C (2 mg/ml, Sigma-Aldrich) dissolved in PBS
(20 mg/kg) or an equivalent volume of PBS at embryonic day 9.5. At postnatal
day 21, tissues were dissected from pups. For macaque models, cynomolo-
gusmonkeys (Macaca fascicularis) (4 years old; all males) were given oral halo-
peridol (0.25–0.5 mg/kg; Wako Pure Chemical Industries) or vehicle for
2 months (Shibuya et al., 2010). After transiently separating two male monkey
neonates (2 weeks old) from dams, neonates received subcutaneous admin-
istration of human recombinant EGF (0.3 mg/kg, Funakoshi) for seven times
over 11 days and then quickly returned to their dams. Preliminary behavioral
assessment of the EGF-treated monkeys was performed at ages of 4 and 6
years and reported (Nawa et al., 2009). These monkeys were sacrificed at
the age of 4 and 7 years with the overdose of pentobarbital (26 mg/kg;
65 mg/ml). Experiments were subjected to review by the Ethical Committee
of Shinn Nippon Biomedical Lab.
iPS Cells
All procedures for skin biopsy and iPS cell production were approved by the
Keio University School of Medicine ethics committee and RIKEN ethics com-
mittee. The 201B7 iPS cells were kindly provided by Dr. Yamanaka (Takahashi
et al., 2007). For the control WD39, a skin-punch biopsy from a healthy
16-year-old Japanese female obtained after written informed consent was
used to generate iPS cells (Imaizumi et al., 2012). 22q11.2 deletion syndrome
iPS cells (SA001 and KO001) were generated from a 37-year-old Japanese
female patient (Toyosima et al., 2011) and a 30-year-old Japanese female
patient, respectively, using the same method used to generate the WD39
(M.T., unpublished data). 22q11 deletion was characterized by the CGH array
analysis (Figure S3). Production and maintenance of iPS cells were performed
according to the previous studies (Imaizumi et al., 2012; Takahashi et al.,
2007). All the iPS cells and differentiated neuronal cell lines were characterized
with immunofluorescence staining and their morphologies (Figure S3).
L1 Copy Number Estimation
We performed either Taqman-based quantitative real-time PCR according to
Coufal et al. (2009) with minor modifications (100 or 500 pg DNA as starting
material and single amplicon analysis) or SYBR-Green-based quantitative
real-time PCR according to Muotri et al. (2010). SYBR-Green assay was
performed using 500 pg DNA and Power SYBR Green PCR Master Mix (Life
Technologies). Primers, probe location, and reaction chemistry are listed in
Figure 1A and Table S4. Quantification was performed in triplicate. A nonpara-312 Neuron 81, 306–313, January 22, 2014 ª2014 Elsevier Inc.metric Mann-Whitney U test was employed for two group comparison and
p < 0.05 was considered significant.
Whole-Genome Sequencing
WGS of brain and liver samples from controls and schizophrenia patients was
performed by Complete Genomics, with the paired-end library preparation
and sequencing-by-ligation using self-assembling DNA nanoball (DNB)
(Drmanac et al., 2010). Data process, mapping, and detection of variations
were performed using the software developed by the Complete Genomics
(version 2.2.0.26 and format version 2.2). Among the detectedmobile insertion
elements, we compared the genomic location of L1 insertion between brain
and liver within an individual and identified brain-specific L1 insertions.
Further experimental details are available in the Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2013.10.053.
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